Patents by Inventor Thomas D. Reed

Thomas D. Reed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11946054
    Abstract: Disclosed herein are polynucleotides encoding ligand-inducible gene switch polypeptides, and systems comprising gene switch polypeptides for modulating the expression of a heterologous gene and an interleukin in a host cell. The compositions, methods and systems described herein facilitate ligand dependent expression of polypeptides including but not limited to cytokines and antigen binding polypeptides.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: April 2, 2024
    Assignee: PRECIGEN, INC.
    Inventors: Rutul R. Shah, Thomas D. Reed, Cheryl G. Bolinger
  • Patent number: 11692194
    Abstract: Disclosed herein are polynucleotides encoding ligand-inducible gene switch polypeptides, and systems comprising gene switch polypeptides for modulating the expression of a heterologous gene and an interleukin in a host cell. The compositions, methods and systems described herein facilitate ligand dependent expression of polypeptides including but not limited to cytokines and antigen binding polypeptides.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: July 4, 2023
    Assignee: PRECIGEN, INC.
    Inventors: Rutul R. Shah, Thomas D. Reed, Cheryl G. Bolinger
  • Publication number: 20200283778
    Abstract: Disclosed herein are polynucleotides encoding ligand-inducible gene switch polypeptides, and systems comprising gene switch polypeptides for modulating the expression of a heterologous gene and an interleukin in a host cell. The compositions, methods and systems described herein facilitate ligand dependent expression of polypeptides including but not limited to cytokines and antigen binding polypeptides.
    Type: Application
    Filed: May 22, 2020
    Publication date: September 10, 2020
    Applicant: PRECIGEN, INC.
    Inventors: Rutul R. SHAH, Thomas D. Reed, Cheryl G. Bolinger
  • Publication number: 20190343967
    Abstract: The present invention relates to methods and compositions for treating, ameliorating or preventing a disease or disorder in a subject by introducing into cells of the subject a therapeutic gene switch construct that controls expression of one or more therapeutic products.
    Type: Application
    Filed: April 22, 2019
    Publication date: November 14, 2019
    Applicant: Intrexon Corporation
    Inventors: Bethany Lynn MERENICK, Robert P. Beech, Thomas D. Reed, Anna P. Tretiakova, Richard E. Peterson
  • Patent number: 10314926
    Abstract: The present invention relates to methods and compositions for treating, ameliorating or preventing a disease or disorder in a subject by introducing into cells of the subject a therapeutic gene switch construct that controls expression of one or more therapeutic products.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: June 11, 2019
    Assignee: Intrexon Corporation
    Inventors: Bethany Lynn Merenick, Robert P. Beech, Thomas D. Reed, Anna P. Tretiakova, Richard E. Peterson
  • Publication number: 20190016765
    Abstract: The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. The localization signals are utilized as research tools or are linked to therapeutics. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize therapeutics, experimental compounds, peptides, proteins and/or other macromolecules to the endoplasmic reticulum of eukaryotic cells. The polypeptides of the invention optionally include linkage to reporters, epitopes and/or other experimental or therapeutic molecules. The invention also encompasses polynucleotides encoding the localization signals and vectors comprising these polynucleotides.
    Type: Application
    Filed: June 21, 2018
    Publication date: January 17, 2019
    Applicant: Intrexon Corporation
    Inventor: Thomas D. REED
  • Publication number: 20180333486
    Abstract: This invention relates to the field of therapeutics. Most specifically invention provides methods of generating in vitro engineered immune cells conditionally expressing interleukin-12 (IL-12) and one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals.
    Type: Application
    Filed: May 24, 2018
    Publication date: November 22, 2018
    Applicant: Intrexon Corporation
    Inventors: Robert P. Beech, Thomas D. Reed
  • Publication number: 20180291384
    Abstract: Disclosed herein are polynucleotides encoding ligand-inducible gene switch polypeptides, and systems comprising gene switch polypeptides for modulating the expression of a heterologous gene and an interleukin in a host cell. The compositions, methods and systems described herein facilitate ligand dependent expression of polypeptides including but not limited to cytokines and antigen binding polypeptides.
    Type: Application
    Filed: January 10, 2018
    Publication date: October 11, 2018
    Inventors: Rutul R. SHAH, Thomas D. REED, Cheryl G. BOLINGER
  • Patent number: 10046049
    Abstract: This invention relates to the field of therapeutics. Most specifically invention provides methods of generating in vitro engineered immune cells conditionally expressing interleukin-12 (IL-12) and one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: August 14, 2018
    Assignee: Intrexon Corporation
    Inventors: Robert P. Beech, Thomas D. Reed
  • Patent number: 10036026
    Abstract: A method for using cloning vector plasmids to produce DNA molecules, such as transgenes, in a single cloning step. The transgenes can be used for the purpose of gene expression or analysis of gene expression. The plasmid cloning vectors are engineered to minimize the amount of manipulation of DNA fragment components by the end user of the vectors and the methods for their use. Transgenes produced using the invention may be used in a single organism, or in a variety of organisms including bacteria, yeast, mice, and other eukaryotes with little or no further modification.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: July 31, 2018
    Assignee: Intrexon Corporation
    Inventor: Thomas D. Reed
  • Publication number: 20180126007
    Abstract: The present invention relates to methods and compositions for treating, ameliorating or preventing a disease or disorder in a subject by introducing into cells of the subject a therapeutic gene switch construct that controls expression of one or more therapeutic products.
    Type: Application
    Filed: June 29, 2017
    Publication date: May 10, 2018
    Applicant: Intrexon Corporation
    Inventors: Bethany Lynn MERENICK, Robert P. Beech, Thomas D. Reed, Anna P. Tretiakova, Richard E. Peterson
  • Publication number: 20180023089
    Abstract: A method for using cloning vector plasmids to produce DNA molecules, such as transgenes, in a single cloning step. The transgenes can be used for the purpose of gene expression or analysis of gene expression. The plasmid cloning vectors are engineered to minimize the amount of manipulation of DNA fragment components by the end user of the vectors and the methods for their use. Transgenes produced using the invention may be used in a single organism, or in a variety of organisms including bacteria, yeast, mice, and other eukaryotes with little or no further modification.
    Type: Application
    Filed: August 13, 2015
    Publication date: January 25, 2018
    Inventor: Thomas D. REED
  • Publication number: 20170260244
    Abstract: The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. The localization signals are utilized as research tools or are linked to therapeutics. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize therapeutics, experimental compounds, peptides, proteins and/or other macromolecules to the endoplasmic reticulum of eukaryotic cells. The polypeptides of the invention optionally include linkage to reporters, epitopes and/or other experimental or therapeutic molecules. The invention also encompasses polynucleotides encoding the localization signals and vectors comprising these polynucleotides.
    Type: Application
    Filed: March 6, 2017
    Publication date: September 14, 2017
    Applicant: Intrexon Corporation
    Inventor: Thomas D. REED
  • Patent number: 9724430
    Abstract: The present invention relates to methods and compositions for treating, ameliorating or preventing a disease or disorder in a subject by introducing into cells of the subject a therapeutic gene switch construct that controls expression of one or more therapeutic products.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: August 8, 2017
    Assignee: Intrexon Corporation
    Inventors: Bethany Lynn Merenick, Robert P. Beech, Thomas D. Reed, Anna P. Tretiakova, Richard E. Peterson
  • Publication number: 20170191027
    Abstract: The present invention relates to methods and compositions for treating a subject comprising destroying diseased cells in the subject. The methods comprise obtaining a population of cells from a subject and determining the activity of at least one disease marker gene within the population of the obtained cells. A polynucleotide molecule that encodes a polypeptide that is lethal to the cells is then introduced into the cells, where the expression of the lethal polypeptide is controlled by the promoter of at least one of the disease marker genes previously identified. After introduction of the polynucleotide, the cells are treated with conditions to induce expression of the lethal polypeptide to destroy the cells that are expressing the disease marker gene(s). After destruction of the diseased cells, the remaining live cells, which did not express the lethal polypeptide to an extent necessary to kill the cells, are separated from the dead cells, and the live cells are restored to the subject.
    Type: Application
    Filed: January 27, 2017
    Publication date: July 6, 2017
    Applicant: Intrexon Corportion
    Inventors: Thomas D. REED, Robert P. BEECH
  • Publication number: 20170145520
    Abstract: The present invention relates to methods and compositions for diagnosing a disease or disorder in a subject by introducing into cells of the subject a diagnostic gene switch construct and monitoring expression of a reporter gene. The invention further relates to methods and compositions for monitoring the progression of a disease or disorder or the effectiveness of a treatment for a disease or disorder.
    Type: Application
    Filed: December 5, 2016
    Publication date: May 25, 2017
    Applicant: Intrexon Corporation
    Inventors: Robert P. BEECH, Thomas D. Reed, Robert Patzig
  • Publication number: 20170128569
    Abstract: This invention relates to the field of therapeutics. Most specifically invention provides methods of generating in vitro engineered immune cells conditionally expressing interleukin-12 (IL-12) and one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals.
    Type: Application
    Filed: September 26, 2016
    Publication date: May 11, 2017
    Applicant: Intrexon Corporation
    Inventors: Robert P. BEECH, Thomas D. REED
  • Patent number: 9617317
    Abstract: The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. The localization signals are utilized as research tools or are linked to therapeutics. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize therapeutics, experimental compounds, peptides, proteins and/or other macromolecules to the endoplasmic reticulum of eukaryotic cells. The polypeptides of the invention optionally include linkage to reporters, epitopes and/or other experimental or therapeutic molecules. The invention also encompasses polynucleotides encoding the localization signals and vectors comprising these polynucleotides.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: April 11, 2017
    Assignee: Intrexon Corporation
    Inventor: Thomas D. Reed
  • Patent number: 9605316
    Abstract: The present invention relates to methods and compositions for diagnosing a disease or disorder in a subject by introducing into cells of the subject a diagnostic gene switch construct and monitoring expression of a reporter gene. The invention further relates to methods and compositions for monitoring the progression of a disease or disorder or the effectiveness of a treatment for a disease or disorder.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: March 28, 2017
    Assignee: Intrexon Corporation
    Inventors: Robert P. Beech, Thomas D. Reed, Robert Patzig
  • Patent number: 9492482
    Abstract: This invention relates to the field of therapeutics. Most specifically invention provides methods of generating in vitro engineered immune cells conditionally expressing interleukin-12 (IL-12) and one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: November 15, 2016
    Assignee: Intrexon Corporation
    Inventors: Robert P. Beech, Thomas D. Reed